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Abstract
Following a long period when the effectiveness of existing mono-therapies for antimalarials was
steadily declining with no clear alternative, most malaria-endemic countries in Africa and Asia have
adopted artemisinin combination therapy (ACT) as antimalarial drug policy. Several ACT drugs
exist and others are in the pipeline. If properly targeted, they have the potential to reduce mortality
from malaria substantially. The major challenge now is to get the drugs to the right people. Current
evidence suggests that most of those who need the drugs do not get them. Simultaneously, a high
proportion of those who are given antimalarials do not in fact have malaria. Financial and other
barriers mean that, in many settings, the majority of those with malaria, particularly the poorest,
do not access formal healthcare, so the provision of free antimalarials via this route has only limited
impact. The higher cost of ACT creates a market for fake drugs. Addressing these problems is now
a priority. This review outlines current evidence, possible solutions and research priorities.
Background
The corner-stone of case-management of malaria is the
early identification and treatment of those with mild dis-
ease with an effective antimalarial. In principle, almost all
deaths due to malaria in children and pregnant mothers
are avoidable, since patients can be treated with antima-
larial drugs which are now available in every country. For
a long time, clinicians were restricted to monotherapies
which, whilst highly effective in the 1960s, had gradually
lost their efficacy due to drug resistance, particularly in
Asia and subsequently in East Africa. A prolonged debate
about how quickly to introduce artemisinin combination
therapy (ACT) largely revolved around the issues of cost
and sustainability; their efficacy was never in doubt [1-3].
The advent of the Global Fund and substantial funding for
purchase of ACT means that most countries in Africa and
Asia feel able to change over to the use of ACT as a policy.
Translating policy into practice and ensuring that ACT
reaches the majority of children and vulnerable adults
with malaria has, however, proved very challenging. This
is not particularly surprising. Prior to the introduction of
ACT, it was already known that many, and the majority in
some settings, of children with clinical malaria did not
receive an antimalarial of any sort. Substituting ACT for
existing first-line antimalarials, even if completely effec-
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tive, was therefore likely to have limited impact, although
limited impact is far preferable to no impact at all. For the
impact of ACT (and any successors to ACT) to be closer to
their potential, policymakers will have to think seriously
about how best to improve delivery and targeting of anti-
malarials. If this is achieved, it could lead to lasting health
gains. However, it is important to note that in some set-
tings the epidemiology of malaria is changing, generally
for the better [4]. This is entirely welcome and the intro-
duction of ACT may have played a significant part. It does,
however, mean that it cannot safely be assumed that some
of the strategies, which worked when malaria was by far
the most common cause of potentially fatal febrile illness,
will necessarily remain appropriate. This review will out-
line the evidence for the problems with getting antimalar-
ials to the right people, examine some of the potential
solutions that have been suggested and finish by consid-
ering some of the issues which may emerge as malaria
incidence decreases either due to attempts to eliminate or
substantially control malaria or for other reasons.
Evidence for the mis-targeting of antimalarials
There is overwhelming evidence that the majority of those
with malaria, particularly in Africa, do not get antimalar-
ials effectively. This applies to all antimalarial classes, not
just to ACT, and is, therefore, a major systems failure. Evi-
dence from across Africa demonstrates that there are mul-
tiple steps at which delivery of antimalarials may fail.
Evidence from Asia and South America is sparser, but les-
sons from Asia may be important as the burden of disease
in some parts of Africa reduces. The first step is that many
children and adults with febrile illness that could be
malaria are treated at home, often with ineffective treat-
ment [5-7]. Of those who are taken for some form of
assessment, the majority are taken to the informal sector
[8]. What constitutes the informal sector varies for each
local setting and can include traditional healers, chemical
or medicine sellers or small shops that sell drugs or other
unregulated providers. Of those who do present to the
informal sector, the proportion receiving an antimalarial
varies. In most informal settings there are no diagnostic
facilities available and targeting is largely random: in
some, less than 20% of those with symptoms compatible
with malaria are given an antimalarial [9]; elsewhere, it
can be as high as 75%, although ineffective treatment with
monotherapy is common [10] and prescriptions may be
in sub-therapeutic doses, prescribed by unqualified staff
[11,12]. Of the minority who do access formal health
care, malaria is the default diagnosis and an antimalarial
will usually be prescribed [13], although this will not nec-
essarily be an effective antimalarial: non-ACT antimalar-
ials continue to be prescribed in the public sector in areas
where the local alternative monotherapy has convincingly
failed [14]. Once ACT use becomes the norm the propor-
tion treated with ineffective drugs tends to decline
[15,16]. The reasons for this are complex [17], and simple
solutions are unlikely to be effective. The continuing use
of failed drugs is probably even more common in the pri-
vate sector where price is a major issue, and the continu-
ing use of artemisinin monotherapy is a serious worry for
the development of drug resistance [18].
There are multiple barriers to accessing formal healthcare
and unfortunately these are likely to fall most on the
poorest, who, in the majority of cases, are those most
likely to have malaria [19]. These barriers include per-
ceived quality of care [20], lack of knowledge [21,22], dis-
tance from health services [23], transport costs, treatment
costs [22,24], difficulties in finding care for other children
if the parent or guardian accesses care, opportunity costs
(which may make up the majority of formal healthcare
episode costs to the family) and, sometimes, difficulties
for mothers in getting permission and funds to attend
health centres [25-28]. Even where drugs are not subsi-
dized, the indirect costs of care exceed the direct costs
[29]; free drugs do not solve this problem. Local concep-
tualization of disease also affects the decision to use for-
mal healthcare [30-32].
Most of those who are given an antimalarial do not have 
malaria
There is now good evidence from across Africa and
increasingly from Asia that, in most formal healthcare set-
tings where ACT are provided, a substantial proportion,
and often the majority of antimalarials are given to chil-
dren and adults who have no parasites and, therefore, do
not have malaria [33,34]. This is also likely to be true in
the informal sector. In low-transmission settings, as little
as 1% of those given an antimalarial actually have para-
sites and even in high transmission settings the majority
of those given an antimalarial do not have parasites [35].
This has been found to be more of a problem in adults
than children although data are sparse. The problem of
over-diagnosis is, therefore, likely to increase as malaria
incidence declines. It is not just a problem for malaria; sig-
nificant bacterial causes of fever are likely to be missed
[36]. Where microscopy is available it usually only has a
limited impact on treatment decisions [33,34]. Several
studies demonstrate that those with a positive slide are
almost inevitably given an antimalarial and those with
negative slides are also in half or more of cases given an
antimalarial, which raises interesting questions as to why
the slide was requested in the first place. Providing rapid
diagnostic tests (RDT) for malaria has been shown to have
limited impact [33,35], although in some situations,
where prolonged training was provided or significant
supervision is available, it can trigger a change in prescrib-
ing practice. The reasons for over-diagnosis of malaria are
multifaceted, and any attempts to change practice will
have to take this into account [37]. Designing strategies to
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address this is not made easier by the fact that national
and WHO guidance on this subject remain ambiguous,
essentially supporting a policy of testing for malaria in
young children, but providing antimalarial treatment
regardless of the test result if the clinician suspects
malaria. Since clinicians almost always have these suspi-
cions, the outcome is inevitable.
The problem of fake drugs
Sub-standard drugs, including antimalarials, are wide-
spread in Africa and Asia. Completely fake drugs are rare
where drugs are cheap. ACTs have a much higher retail
value than older monotherapies, so the difference in the
cost of manufacturing a fake drug and purchase cost pro-
vides potential for considerable profits. Fake artesunate is
now widespread in South-East Asia, with studies in some
countries reporting the majority of artemisinin drugs
being fakes [38]. Counterfeit drugs have already pene-
trated the African market to some degree at least [39]. The
fakes are highly sophisticated, including convincing pack-
aging, holograms and marketing, and represent a major
technical and law-enforcement challenge [40]. Every
malaria patient treated with fake ACT is in danger of pro-
gressing to severe illness and in some cases of dying. On
the wider scale, if fake artemisinins penetrate the market
to a great degree, they may precipitate a collapse of confi-
dence in ACT. Currently, the only thing that prevents this
becoming a major public health tragedy in Africa is the
relatively high cost of fake ACT, which make it unafforda-
ble to the poorest, who are the group with the highest risk
of true malaria. Increasingly sophisticated methods of
detecting fake drugs are a major step in the right direction,
but will only be effective when linked to a functioning
drug-control system and legal sanctions that have a realis-
tic chance of being applied.
Costs, price and the private market
The majority of the poorest people cannot afford to access
healthcare in the formal sector. This is due to transport
and opportunity costs in particular [29]. The time of year
when malaria is most common in most parts of Africa
(during the rainy season) is also the period when the
opportunity costs are highest and the transport is most
difficult. Only in a minority of settings in Africa is formal
healthcare the major provider for acute febrile illness in
children. [41]. In reality, the private informal system
(meaning shops rather than private formal doctors) pro-
vides the bulk of care in many countries. There is evidence
that shopkeepers, if properly trained, can improve their
targeting of antimalarials [42] and this intervention can
be made cost-effective [43], but in the private market ACT
drugs remain very expensive, with prices of over 10 USD
per treatment not being uncommon. This provides a dou-
ble-jeopardy, with the poorest not being able to afford to
access the formal health care sector, where drugs are free,
or heavily subsidized, and not being able to afford anti-
malarials which are effective in the private sector even if
they are properly diagnosed, which they often are not.
Serious attempts are now being made to design a subsidy
(the Affordable Medicines Fund malaria, (AMFm) which
could be effective in reducing the price of antimalarials in
the private sector in the periphery to address this problem,
but this is a challenging undertaking. ACT is cost effective
in almost all settings where there is drug-resistance, which
in practice means almost everywhere provided they are
targeted to the right people [29]. This is primarily due to
the fact that future expensive episodes of malaria, or in the
worst case hospital admissions, are avoided by interven-
ing early. Cost-effectiveness does not necessarily translate
into willingness to pay for them at or near their market
price [44]. Those who have children with febrile illness are
often not willing, or able, to pay the current retail price of
ACT available in the private sector.
Potential solutions and gaps in current knowledge
A number of solutions exist to each of the problems iden-
tified above. Policymakers currently do not know which
are the most effective or, more realistically, which ones are
most effective in what settings. The local healthcare struc-
ture, epidemiology of malaria and socio-economic factors
are all likely to play a major part in determining what is
appropriate in a given setting. Unfortunately, far more
effort has gone into determining which antimalarials are
efficacious than determining how to deliver them effec-
tively, and health services are now having to play catch-
up. A drug which is 90% efficacious but delivered to only
20% of those who need it clearly has limited effectiveness
at an operational level.
For access, the solutions fall broadly into three categories.
The first is to promote the use of home- or community-
based care. The principle of this is for early recognition
and treatment of malaria by volunteers or individuals
with limited training and support, equipped with stocks
of antimalarial drugs, which they can prescribe. In such
programmes, febrile children are typically treated pre-
sumptively with antimalarials. The proximity to the home
in comparison to formal healthcare settings can reduce
barriers to people accessing formal healthcare. Recogniz-
ing that many antimalarial treatments are distributed
through the private sector, which is often used in prefer-
ence to formal services even when these are easy to access
[7], the second solution is to build upon this practice and
improve the services of the private sector. The third solu-
tion is to improve the existing formal healthcare systems,
so that people are more likely to use them, and to reduce
or remove all out-of-pocket payments to reduce the direct
cost of care. All three of these broad approaches have
advocates and in practice they are not mutually exclusive
and their relative effectiveness will depend on the setting.
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Home-based care in rural environments has been demon-
strated to have an impact on morbidity [45] and mortality
[46], but several other studies failed to find an impact or
found limited impact. The evidence around this has been
recently reviewed in Malaria Journal [47]. No data on the
health impact of home treatment with ACT are yet availa-
ble, although evidence from pilot studies suggests that the
delivery of ACT through this route is operationally both
feasible and acceptable [48,49]. The disadvantages of
delivering ACT through the home-based care route are
that it will inevitably increase wastage of the drug and is
likely to drive forward resistance. Set against this, it cer-
tainly would increase the number of people that get an
ACT, although at this stage it is not clear whether that
would be an increase in people who get them appropri-
ately. It is likely that home-based care is most useful in
areas where malaria is one of the most common causes of
acute febrile illness and in rural areas where physical
access to formal healthcare is problematic. It is not clear
how sustainable this is as a system for delivering ACT on
a wide scale.
Improving the service of the informal private sector
(meaning shops rather than meaning private doctors)
may require better regulation of drug sellers and shops
alongside training [12]. Trials of training interventions
have had promising results for improving prescribing
behaviour of drug sellers in Kenya [42]. The biggest barrier
to using ACT widely in the private sector is their very high
cost in that sector. The possibility of a global subsidy has
been raised [2,50] which, in addition to the current sub-
sidy for public sector distribution from the Global Fund,
would encompass all ACT distribution channels, thus
minimizing their cost and (it is hoped) bringing them
down to the price of any other antimalarial. There are a
number of major technical challenges, not least of which
is to find sufficient donor enthusiasm to ensure sustaina-
bility, but if ACTs could be provided cheaply through the
private sector, the possibility of distributing ACTs through
shops in hard-to-reach areas would become realistic. Key
to this would be maintaining the low cost of ACTs
throughout the distribution chain and there needs to be
careful investigation of various methods of doing this at
every stage.
Where the quality of service in the public sector improves,
and this is perceived by the local population, there is evi-
dence of increasing access and demand [51,52]. Incorpo-
rating patient education into consultations has been
suggested to improve recognition of malaria symptoms,
compliance with drug regimens and potentially earlier
access to formal sector care. Providing treatment free-of-
charge also leads to a change in healthcare utilization
[53], although challenges with informal payments for
healthcare remain. These may be overcome if health
workers are provided with additional financial support
from their employer. What is currently lacking is evidence
that this translates into improved malaria-associated
health outcomes.
All three of these approaches need to be tried both opera-
tionally and in comparison with one-another in settings
with different transmission intensities and healthcare sys-
tems. There is the potential to waste a lot of drugs and
resources for very little health benefit if they are not
underpinned by adequate research before deployment.
Improving targeting
In settings where microscopy is already available, there is
now clear evidence that simply deploying rapid diagnostic
tests or other technologies makes relatively limited differ-
ence. Where training and supervision can be provided,
prescriber compliance with the results of tests can be
improved, but it is likely that far more complex measures
are likely to be needed to change prescriber behaviour sus-
tainably. Introducing rapid diagnostic tests can be highly
cost-effective [54], when the results lead to a change in
prescribing practice [55]. The reasons that, in the formal
sector, the prescription of antimalarials is almost a default
for any child and, in reality, any adult for whom there is
no alternative diagnosis, even in the absence of parasites
on microscopy or rapid diagnostic tests, are complex. Fur-
ther investigation into the reasons for this behaviour is
likely to be needed before it is possible to design complex
interventions to tackle it. This may involve training of
healthcare workers, novel approaches to providing incen-
tives and changing the perceptions of patients. Challenges
to training schemes for improving the targeting of ACT by
formal sector health workers include the complexity of
current guidelines [56] and the perception that patients
want antimalarials even when there is no evidence that
this is true [57].
Fake drugs
There needs to be an investment in developing rapid test-
ing for fake drugs at point-of-purchase or nearby. This
needs to be linked to epidemiological sampling, which
maximizes the chances of identifying fake drugs early on.
Relatively little is known about the flow of drugs from
areas where fakes are manufactured through to potential
target markets in Africa and understanding this better will
be key to early identification of the problem.
Asia
Whilst the majority of effort tends to be concentrated in
Africa, because that is where the burden of falciparum
malaria is greatest, Asia presents specific challenges for
deployment of ACT. Many of the problems found in
Africa of low coverage, poor targeting and monotherapy
in the private sector are replicated in Asia [58]. In South-
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East Asia, there is already a concern about an increasing
tolerance to artemisinins by parasites [59]. Putting artem-
isinins in combinations can slow, but is unlikely to stop
the development and spread of this tolerance and, if it
becomes significant, the implications would be very
severe. South-East Asia is also the current focus of fake
drugs. On the other hand, the very successful use of diag-
nostic services, both microscopy and RDTs, in South-East
Asia may provide models for other settings. In South Asia,
the major problem is two-fold; the majority of malaria is
vivax malaria and the minority of febrile illness is malaria,
even in areas considered highly endemic. ACT drugs do
work against vivax [60,61], but this is generally an expen-
sive and inefficient approach to treating a disease, which
can be very well treated in most cases with chloroquine.
The problem is that diagnostic services are not widely
accessible and, where they are available, species differen-
tiation into falciparum and vivax malaria is not always
reliable, particularly in those areas where malaria is most
common. Policymakers are therefore left with two
options: either improving diagnosis and species differen-
tiation so that ACT is targeted to those with falciparum
malaria, or a more blanket approach, which will lead to
substantial wastage of the drugs, either on people who do
not have malaria, or who have vivax malaria and could be
treated with much cheaper alternatives for which there is
no likely global shortage. Since falciparum is the minority
species and malaria a minority cause of potentially serious
febrile illness, the blanket approach is also likely to have
a limited public health effect, or at worse a detrimental
effect on treatment of febrile illness, much of which is bac-
terial. This is not a trivial problem: since there are more
people living in potentially malaria-endemic areas of
India, Pakistan, Bangladesh and Afghanistan than there
are in Africa, even relatively small wastage of drugs could
have substantial impact on supply.
Wide-scale deployment of RDTs in Asia is one possibility,
but the current technology for species-specific RDTs is not
well developed for field use, is expensive, and lacks data
to demonstrate the advantages (economic and clinical) of
this strategy over existing services or alternatives (i.e.
microscopy). Where most febrile illness is not malaria,
deployment of RDTs will also result in negative diagnosis
in the majority of cases. Detection of falciparum will also
be rare, since this is the minority species. At the opera-
tional level, this may result in similar problems to those
found in Africa, where antimalarials are prescribed regard-
less, as clinicians come to disbelieve what are, in fact gen-
erally correct negative results. In most areas of Asia,
transmission of disease is unstable and varies by season
and geographical area [62]. One solution may be to take
advantage of this instability by deploying the cheaper and
more robust falciparum-specific RDTs and ACT at com-
munity level at the beginning of the falciparum transmis-
sion season in areas of endemicity. To deploy this strategy
effectively in underserved areas at community level will
require the generation of effectiveness data in the opera-
tional setting and efficient logistics systems.
Elimination and the reduction of malaria-impact on 
deployment of ACT
Malaria incidence appears to be decreasing in a number of
countries in Africa [63,64]. Deployment of ACT is likely to
have played a part in this, especially in moving from low
to very low transmission, due to the gametocidal activity
of the drugs. This wholly welcome news does, however,
make some of the problems highlighted above more,
rather than less, challenging. Home-management of
malaria (HMM, HBMF) and other methods which
increase the syndromic management of febrile episodes
with ACT is likely to have diminishing returns as some
countries move to a situation where only a minority, and
eventually only a small minority of those with potentially
serious causes of fever have malaria. Reduction in preva-
lence of malaria at presentation will exacerbate the prob-
lem of poor targeting in the formal healthcare sector. In
time, it may be possible to alter the perceptions of doctors
about the risk of malaria. This will have to be handled
carefully, or endemic countries could move from a situa-
tion where most of those given ACT do not have malaria
but all true cases are treated, to one where cases of true
malaria are missed. The reduction in the incidence of
malaria is likely additionally to have an impact over time
on immunity, and the age-range where missed cases could
prove fatal may increase. At present, in much of Africa, it
is possible to target most activities (eg HMM) to children
under five years of age and pregnant women. This may not
remain sensible policy in the longer term, which signifi-
cantly increases the logistical challenges and potential
costs.
Conclusion
The ACT drugs have the potential to transform the current
state of malaria in Africa and elsewhere. Simply deploying
them using current channels will, however, lead to a lim-
ited impact. It is essential that as much effort is put into
investigating new ways of delivering drugs to those who
need them, as has gone into developing the drugs in the
first place. This needs to be followed by a rational policy
discourse based on the assumption that complex prob-
lems are likely to need complex solutions. There is always
a tendency to look for quick fixes based on a single solu-
tion, but there is no evidence that this will work in the
case of ACT deployment. The policy, therefore, needs to
be turned into practice in a sustainable way, and funding
secured for this. This is no small task but the potential
benefits are great and it has to be undertaken.
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